United Therapeutics has completed enrollment in one of two Phase III clinical trials for Ovarex, the company's experimental drug for patients with late-stage ovarian cancer. The trial enrolled 177 people. The two upcoming Phase III trials will be conducted at more than 60 research centers in the U.S.
Ovarex is a monoclonal antibody for patients with Stage III/IV advanced ovarian cancer who are also being treated with chemotherapy. The investigational drug targets a protein expressed in most cases of ovarian cancer, and it is designed to help patients' immune systems recognize and more effectively fight the cancer.